SCHEMBL5778007

SCHEMBL5778007

O=S(=O)(Nc1cc(Cl)c2c(c1)CCNCC2)c1cccc(C(F)(F)F)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
TSHR P16473 1/20 0.47
HTR6 P50406 4/20 0.47
NR3C1 P04150 1/20 0.47
PGR P06401 1/20 0.47
AR P10275 1/20 0.47
ESR2 Q92731 1/20 0.47
PKM P14618 1/20 0.46
PKLR P30613 1/20 0.46
HSD17B2 P37059 1/20 0.46
CCR2 P41597 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
HTR2C P28335 2/20 0.45
HTR2B P41595 2/20 0.45
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5780409 0.84 HTR6 (0.66) HTR6PGRPKMKMT2AMEN1
SCHEMBL5781608 0.83 HTR6 (0.69) LMNANPSR1TSHRHTR6NR3C1
SCHEMBL6625953 0.79 LMNA (0.53) LMNANPSR1TSHRHTR6NR3C1
SCHEMBL10565363 0.73 PKM (0.62) LMNATSHRHTR6PKMPKLR
SCHEMBL7572556 0.72 PGR (0.67) TSHRNR3C1PGRARESR2
SCHEMBL3762909 0.71 PGR (0.77) TSHRNR3C1PGRARESR2
SCHEMBL3353767 0.70 MAPT (0.45) LMNANPSR1TSHRHTR6NR3C1
SCHEMBL1960175 0.70 HTR6 (0.70) LMNAHTR6PKMPKLRKMT2A
SCHEMBL5778392 0.70 HTR6 (0.66) LMNAHTR6PGRPKMKMT2A
SCHEMBL5781207 0.70 HTR6 (0.74) LMNAHTR6PGRPKMHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1487801-B1 7-ARYLSULFONAMIDO-2,3,4,5-TETRAHYDRO-1H-BENZO¬D|AZEPINE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY FOR THE TREATMENT OF CNS DISORDERS GLAXO GROUP LTD (GB) 2006-04-19 EP claimed
US-20050090496-A1 Sulphonyl compounds with 5-ht6 receptor affinity GLAXO GROUP LIMITED (GB) 2005-04-28 US claimed
US-20050090485-A1 7-Arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo'diazepine derivatives with 5ht6 receptor affinity for the reatment of cns disorders GLAXO GROUP LIMITED (GB) 2005-04-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090496-A1 Sulphonyl compounds with 5-ht6 receptor affinity HTR6, HTR4, HTR5A LMNA 4697/4885NPSR1 22/4885TSHR 296/4885
US-20050090485-A1 7-Arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo'diazepine derivatives with 5ht6 receptor affinity for the reatment of cns disorders HTR6, HTR7, HTR2A LMNA 3284/4885NPSR1 41/4885TSHR 191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.